Role of Physical Therapy Intervention and Gene Therapy on Muscular Dystrophies, Current Status and Future Perspectives: A Narrative Review : Role of Physical Therapy Intervention and Gene Therapy

Hafsa Abid; Saleh Shah; Ali Ahmed; Nazira Habib; Mah Bibi; Muhammad Ibrahim

doi:10.54393/pjhs.v5i01.1253

Authors

Hafsa Abid Superior University, Lahore, Pakistan
Saleh Shah Department of Physical Therapy and Rehabilitation, Superior University, Lahore, Pakistan
Ali Ahmed Faculty of Nursing and Midwifery, Ziauddin University, Karachi, Pakistan
Nazira Habib Faculty of Nursing and Midwifery, Ziauddin University, Karachi, Pakistan
Mah Bibi Faculty of Nursing and Midwifery, Ziauddin University, Karachi, Pakistan
Muhammad Ibrahim Faculty of Nursing and Midwifery, Ziauddin University, Karachi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i01.1253

Keywords:

Muscular Dystrophy, Gene Therapy, Adenovirus, Molecular Pathogenesis

Abstract

Muscular dystrophies form a collection of genetic disorders marked by progressive muscle weakness and degeneration. The identification of the majority of responsible genes has enabled precise diagnosis and subtype-specific anticipatory care. Over the years, various therapies, encompassing genetic, cellular, and pharmacological approaches, have emerged for muscular dystrophies. This narrative review thoroughly explores the ongoing developments in muscular dystrophy therapeutics, including antisense therapy, CRISPR, gene replacement, cell therapy, based gene therapy Adeno-associated viral vector (AAV), and disease-modifying small molecule compounds. The review is particularly significant as it reflects advancements in supportive medicine that have altered the standard of care, leading to an overall improvement in the quality of life, clinical course and survival for affected individuals. In this study, our focus is on the clinical manifestations, molecular pathogenesis, diagnostic strategies, and therapeutic advancements related to this group of conditions. The study involved the review of 20 pertinent English-language articles, publications, reports, and online resources.

References

Mercuri E, Bönnemann CG, Muntoni F. Muscular dystrophies. The Lancet. 2019 Nov; 394(10213): 2025-38. doi: 10.1016/S0140-6736(19)32910-1. DOI: https://doi.org/10.1016/S0140-6736(19)32910-1

Swathi S, Chandrasekaran GK, Senthil P. Advanced Physiotherapy Intervention for Muscular Dystrophy. Potential Therapeutic Strategies for Muscular Dystrophy. IntechOpen; 2023. doi: 10.5772/intechopen.113080. DOI: https://doi.org/10.5772/intechopen.113080

Younger DS. Childhood muscular dystrophies. In Handbook of Clinical Neurology. Elsevier 2023 Jan; 195: 461-96. doi: 10.1016/B978-0-323-98818-6.00024-8. DOI: https://doi.org/10.1016/B978-0-323-98818-6.00024-8

Zambon AA and Muntoni F. Congenital muscular dystrophies: What is new? Neuromuscular Disorders. 2021 Oct; 31(10): 931-42. doi: 10.1016/j.nmd.2021.07.009. DOI: https://doi.org/10.1016/j.nmd.2021.07.009

Salari N, Fatahi B, Valipour E, Kazeminia M, Fatahian R, Kiaei A et al. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. Journal of Orthopedic Surgery and Research. 2022 Dec; 17(1): 1-2. doi: 10.1186/s13018-022-02996-8. DOI: https://doi.org/10.1186/s13018-022-02996-8

Datta N and Ghosh PS. Update on muscular dystrophies with focus on novel treatments and biomarkers. Current Neurology and Neuroscience Reports. 2020 Jun; 20: 1-2. doi: 10.1007/s11910-020-01034-6. DOI: https://doi.org/10.1007/s11910-020-01034-6

Osorio AN, Cantillo JM, Salas AC, Garrido MM, Padilla JV. Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. Neurología. 2019 Sep; 34(7): 469-81. doi: 10.1016/j.nrleng.2018.01.001. DOI: https://doi.org/10.1016/j.nrleng.2018.01.001

Comi GP, Niks EH, Vandenborne K, Cinnante CM, Kan HE, Willcocks RJ et al. Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study. Frontiers in Neurology. 2023 Jan; 14: 1095121. doi: 10.3389/fneur.2023.1095121. DOI: https://doi.org/10.3389/fneur.2023.1095121

Crudele JM and Chamberlain JS. AAV-based gene therapies for the muscular dystrophies. Human Molecular Genetics. 2019 Oct; 28(R1): R102-7. doi: 10.1093/hmg/ddz128. DOI: https://doi.org/10.1093/hmg/ddz128

Lanza G, Pino M, Fisicaro F, Vagli C, Cantone M, Pennisi M et al. Motor activity and Becker’s muscular dystrophy: lights and shadows. The Physician and Sportsmedicine. 2020 Apr; 48(2): 151-60. doi: 10.1080/00913847.2019.1684810. DOI: https://doi.org/10.1080/00913847.2019.1684810

Abd El Aziz AS, Abd El Aziz HG, Ali MS. Efficacy of two intervention approaches on functional walking capacity and balance in children with Duchene muscular dystrophy. Journal of Musculoskeletal & Neuronal Interactions. 2021; 21(3): 343.

Bayley K, Parkinson S, Jacoby P, Cross D, Morris S, Vorster N et al. Benefits of powered standing wheelchair devices for adolescents with Duchenne muscular dystrophy in the first year of use. Journal of Pediatrics and Child Health. 2020 Sep; 56(9): 1419-25. doi: 10.1111/jpc.14963. DOI: https://doi.org/10.1111/jpc.14963

Baeza-Barragán MR, Manzanares MT, Vergara CR, Casuso-Holgado MJ, Martín-Valero R. The use of virtual reality technologies in the treatment of Duchenne muscular dystrophy: systematic review. JMIR mHealth and uHealth. 2020 Dec; 8(12): e21576. doi: 10.2196/21576 DOI: https://doi.org/10.2196/21576

Camela F, Gallucci M, Ricci G. Cough and airway clearance in Duchenne muscular dystrophy. Paediatric Respiratory Reviews. 2019 Aug; 31: 35-9. doi: 10.1016/j.prrv.2018.11.001. DOI: https://doi.org/10.1016/j.prrv.2018.11.001

Dhargave P, Nalini A, Nagarathna R, Sendhilkumar R, James TT, Raju TR et al. Effect of yoga and physiotherapy on pulmonary functions in children with duchenne muscular dystrophy–a comparative study. International Journal of Yoga. 2021 May; 14(2): 133. doi: 10.4103/ijoy.IJOY_49_20. DOI: https://doi.org/10.4103/ijoy.IJOY_49_20

Carroll K, Yiu EM, Ryan MM, Kennedy RA, de Valle K. The effects of calf massage in boys with Duchenne muscular dystrophy: a prospective interventional study. Disability and Rehabilitation. 2021 Dec; 43(26): 3803-9. doi: 10.1080/09638288.2020.1753829. DOI: https://doi.org/10.1080/09638288.2020.1753829

de Souza MA, Cezarani A, da Silva Lizzi EA, de Queiroz Davoli GB, Mattiello SM, Jones R et al. The use of the gait profile score and gait variable score in individuals with Duchenne Muscular Dystrophy. Journal of Biomechanics. 2020 Jan; 98: 109485. doi: 10.1016/j.jbiomech.2019.109485. DOI: https://doi.org/10.1016/j.jbiomech.2019.109485

Alemdaroğlu-Gürbüz İ, İpek C, Bulut N, Karaduman A, Yılmaz Ö. The Impact of “Fear of Falling” on Physical Performance, Balance, and Ambulation in Duchenne Muscular Dystrophy. Neuropediatrics. 2022 Aug; 53(05): 330-7. doi: 10.1055/s-0042-1750722. DOI: https://doi.org/10.1055/s-0042-1750722

van As D, Okkersen K, Bassez G, Schoser B, Lochmüller H, Glennon JC et al. Clinical outcome evaluations and CBT response prediction in myotonic dystrophy. Journal of Neuromuscular Diseases. 2021 Jan; 8(6): 1031-46. doi: 10.3233/JND-210634. DOI: https://doi.org/10.3233/JND-210634

Dias RM, Hoshi RA, Vanderlei LC, Monteiro CB, Alvarez MP, Crocetta TB et al. Influence of different types of corticosteroids on heart rate variability of individuals with duchenne muscular dystrophy—a pilot cross sectional study. Life. 2021 Jul; 11(8): 752. doi: 10.3390/life11080752. DOI: https://doi.org/10.3390/life11080752

Kracht KD, Eichorn NL, Berlau DJ. Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy. Expert Opinion on Pharmacotherapy. 2022 Oct; 23(15): 1701-10. doi: 10.1080/14656566.2022.2130246. DOI: https://doi.org/10.1080/14656566.2022.2130246

Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda SI, Yokota T, Aoki Y. Restoring dystrophin expression in Duchenne muscular dystrophy: current status of therapeutic approaches. Journal of Personalized Medicine. 2019 Jan; 9(1): 1. doi: 10.3390/jpm9010001. DOI: https://doi.org/10.3390/jpm9010001

Sun C, Serra C, Lee G, Wagner KR. Stem cell-based therapies for Duchenne muscular dystrophy. Experimental Neurology. 2020 Jan; 323: 113086. doi: 10.1016/j.expneurol.2019.113086. DOI: https://doi.org/10.1016/j.expneurol.2019.113086

Ganassi M and Zammit PS. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies. European Journal of Translational Myology. 2022 Mar; 32(1). doi: 10.4081/ejtm.2022.10064. DOI: https://doi.org/10.4081/ejtm.2022.10064

Shehata ZH, Rabea H, El Sherif R, Abdelrahim ME, Dawoud DM. Estimating Societal Cost of Illness and Patients’ Quality of Life of Duchenne Muscular Dystrophy in Egypt. Value in Health Regional Issues. 2023 Jan; 33: 10-6. doi: 10.1016/j.vhri.2022.08.006. DOI: https://doi.org/10.1016/j.vhri.2022.08.006

Shah MN and Yokota T. Cardiac therapies for Duchenne muscular dystrophy. Therapeutic Advances in Neurological Disorders. 2023 Jul; 16: 17562864231182934. doi: 10.1177/17562864231182934. DOI: https://doi.org/10.1177/17562864231182934

Gianola S, Castellini G, Pecoraro V, Monticone M, Banfi G, Moja L. Effect of muscular exercise on patients with muscular dystrophy: a systematic review and meta-analysis of the literature. Frontiers in Neurology. 2020 Nov; 11: 958. doi: 10.3389/fneur.2020.00958. DOI: https://doi.org/10.3389/fneur.2020.00958

Nakajima T, Sankai Y, Takata S, Kobayashi Y, Ando Y, Nakagawa M et al. Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001). Orphanet Journal of Rare Diseases. 2021 Dec; 16(1): 1-8. doi: 10.1186/s13023-021-01928-9. DOI: https://doi.org/10.1186/s13023-021-01928-9

Lessard I, Gaboury S, Gagnon C, Bouchard K, Chapron K, Lavoie M et al. Effects and acceptability of an individualized home-based 10-week training program in adults with myotonic dystrophy type 1. Journal of Neuromuscular Diseases. 2021 Jan; 8(1): 137-49. doi: 10.3233/JND-200570. DOI: https://doi.org/10.3233/JND-200570

Biressi S, Filareto A, Rando TA. Stem cell therapy for muscular dystrophies. The Journal of Clinical Investigation. 2020 Nov; 130(11): 5652-64. doi: 10.1172/JCI142031. DOI: https://doi.org/10.1172/JCI142031

Iavarone M, Monda E, Vritz O, Albert DC, Rubino M, Verrillo F et al. Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy. Archives of Cardiovascular Diseases. 2022 Sep; 115: 529-37. doi: 10.1016/j.acvd.2022.06.003. DOI: https://doi.org/10.1016/j.acvd.2022.06.003

Hammer S, Toussaint M, Vollsæter M, NESBJØRG M, Røksund OD, Reychler G et al. Exercise training in Duchenne muscular dystrophy: A systematic review and meta-analysis. Journal of Rehabilitation Medicine. 2022; 54. doi: 10.2340/jrm.v53.985. DOI: https://doi.org/10.2340/jrm.v53.985